Data on herceptin for early breast cancer currently insufficient for decision ...( Yesterday Patricia Hewitt the UK's He...)

Data on herceptin for early breast cancer currently insufficient for decision on its use

Yesterday Patricia Hewitt, the UK's Health Secretary, intervened directly to mediate a debate about access to the drug Herceptin for patients with early breast cancer. However, the available evidence on the efficacy and safety of Herceptin for early breast cancer is insufficient to make any reliable judgements, states an editorial by The Lancet published online today (Wednesday November 9, 2005). The UK's National Institute for Health and Clinical Excellence (NICE) should be given time to consider the evidence on the drug and must resist pressure from external groups, whatever the urgency and however well meaning, states The Lancet.

The studies on the use of Herceptin for early breast cancer were recently published in the New England Journal of Medicine (NEJM). An accompanying editorial in the NEJM stated that Herceptin "maybe even a cure" for breast cancer. However, the two studies represent interim efficacy analyses--a type of analyses that may show implausibly large treatment effects. A review in The Journal of the American Medical Association (JAMA) last week said, "clinicians should view the results of such trials with scepticism". The Lancet also notes that the two reports use different dosing regimens, making comparisons and conclusions difficult. Comparisons are further hampered by the omission of crucial overall and disease-free survival data, as well as information on cardiotoxicity. However, it is clear that Herceptin can precipitate severe heart failure in some patients, states the editorial.

The Lancet concludes: "The best that can be said about Herceptin's efficacy and safety for the treatment of early breast cancer is that the available evidence is insufficient to make reliable judgments. It is profoundly misleading to suggest, even rhetorically, that the published data may be indicative of a cure for breast cancerDrug regulatory agencies and bodies such as NICE play an important part in translating research evidence into clinical
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
9-Nov-2005

Page: 1 2
Related medicine news :

1. Study finds cardiac toxicity rates high with herceptin use
2. Lack of response to herceptin may be reversed with addition of a PI3K inhibitor
3. Pot bellies linked to early signs of cardiovascular disease
4. U of M report says early-childhood intervention improves well-being through young adulthood
5. Method shows promise for early detection of pancreatic cancer
6. Treatment for early prostate cancer associated with type of specialist seen
7. Medical management of another condition may not lead to early cancer diagnosis
8. Dasatinib shows high early response rate as first treatment for chronic myelogenous leukemia
9. Study supports activity of GEMZAR in the treatment of early-stage breast cancer
10. Innovative device to treat brain cancer shows promise in early studies
11. Advances in screening and markers improve early detection of colorectal cancer

Post Your Comments: